1. Home
  2. GYRE vs EVER Comparison

GYRE vs EVER Comparison

Compare GYRE & EVER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GYRE
  • EVER
  • Stock Information
  • Founded
  • GYRE 2002
  • EVER 2008
  • Country
  • GYRE United States
  • EVER United States
  • Employees
  • GYRE N/A
  • EVER N/A
  • Industry
  • GYRE Biotechnology: Pharmaceutical Preparations
  • EVER Computer Software: Programming Data Processing
  • Sector
  • GYRE Health Care
  • EVER Technology
  • Exchange
  • GYRE Nasdaq
  • EVER Nasdaq
  • Market Cap
  • GYRE 990.4M
  • EVER 960.3M
  • IPO Year
  • GYRE N/A
  • EVER 2018
  • Fundamental
  • Price
  • GYRE $7.72
  • EVER $26.19
  • Analyst Decision
  • GYRE
  • EVER Strong Buy
  • Analyst Count
  • GYRE 0
  • EVER 6
  • Target Price
  • GYRE N/A
  • EVER $32.33
  • AVG Volume (30 Days)
  • GYRE 221.1K
  • EVER 671.7K
  • Earning Date
  • GYRE 03-17-2025
  • EVER 05-05-2025
  • Dividend Yield
  • GYRE N/A
  • EVER N/A
  • EPS Growth
  • GYRE N/A
  • EVER N/A
  • EPS
  • GYRE 0.05
  • EVER 0.88
  • Revenue
  • GYRE $105,757,000.00
  • EVER $500,190,000.00
  • Revenue This Year
  • GYRE $51.85
  • EVER $27.51
  • Revenue Next Year
  • GYRE $29.83
  • EVER $11.88
  • P/E Ratio
  • GYRE $155.02
  • EVER $30.55
  • Revenue Growth
  • GYRE N/A
  • EVER 73.72
  • 52 Week Low
  • GYRE $7.00
  • EVER $16.63
  • 52 Week High
  • GYRE $19.00
  • EVER $30.03
  • Technical
  • Relative Strength Index (RSI)
  • GYRE 33.88
  • EVER 50.12
  • Support Level
  • GYRE $8.65
  • EVER $27.69
  • Resistance Level
  • GYRE $9.50
  • EVER $30.03
  • Average True Range (ATR)
  • GYRE 1.02
  • EVER 1.67
  • MACD
  • GYRE -0.24
  • EVER -0.29
  • Stochastic Oscillator
  • GYRE 12.81
  • EVER 29.93

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

About EVER EverQuote Inc.

EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.

Share on Social Networks: